Patent ID: 9046522
Filing Date: 2015-06-02
Classification: C07K,C12Q,G01N

Abstract:
1. An in vitro method for diagnosing endometrial cancer in a patient, comprising (a) performing reverse transcription on a uterine tissue or uterine fluid sample from the patient to synthesize cDNA, (b) contacting the cDNA with primers and reagents and specifically amplifying P4HB cDNA, (c) contacting the cDNA with primers and reagents and specifically amplifying GMIP cDNA, wherein the amplifying of P4HB cDNA and the amplifying of GMIP cDNA are not multiplex, and (d) detecting the level of the amplified P4HB cDNA and GMIP cDNA, wherein increased levels of P4HB cDNA and GMIP cDNA compared to a control value indicates the existence of endometrial cancer, wherein the P4HB primers are primer pairs selected from the group consisting of: (i) Forward SEQ ID NO:247: GCTGCGGAAAAGCAACTTC and Reverse SEQ ID NO:248 CTGATCTCGGAACCTTCTGC; (ii) Forward SEQ ID NO:249 GGCTATCCCACCATCAAGTT and Reverse SEQ ID NO:250 TCTTCAGCCAGTTCACGATG; (iii) Forward SEQ ID NO:251 GCAGAGTCCTTGGTGGAGTC and Reverse SEQ ID NO:252 TGGAAGTGATCCCAAATGGT; (iv) Forward SEQ ID NO:253 ACCATTTGGGATCACTTCCA and Reverse SEQ ID NO:254 GGTGACCTCCCCTTCAAAGT; (v) Forward SEQ ID NO:255 CCCCTTGTCATCGAGTTCAC and Reverse SEQ ID NO:256 TGCTCAGTTTGCCGTCATAG; (vi) Forward SEQ ID NO:257 TCACATCCTGCTGTTCTTGC and Reverse SEQ ID NO:258 GTCGCTGTCGATGAAGATGA; (vii) Forward SEQ ID NO:259 GACGGCAGAGAGGATCACAG and Reverse SEQ ID NO:260 TTCTTCCCAACAAGCACCTT; (viii) Forward SEQ ID NO:261 AGCCTGTCAAGGTGCTTGTT and Reverse SEQ ID NO:262 CAAATGGGAGCCAACTGTTT; (ix) Forward SEQ ID NO:263 ACAGCTTCCCCACACTCAAG and Reverse SEQ ID NO:264 CACCGCTCTCCAGGAATTT; and (x) Forward SEQ ID NO:265 GCACGCTGGATGGTTTTAAG and Reverse SEQ ID NO:266 TCATCGTCTTCCTCCATGTCT.